胃癌患者血浆TAFI及TAT的变化及其临床意义

目的 探讨胃癌患者血浆凝血酶激活的纤溶抑制物(thrombin activated fibrinolysis inhibitor,TAFI)和凝血酶-抗凝血酶复合物(thrombin-antithrombin complex,TAT)水平的变化及其与胃癌的关系.方法 收集原发性胃癌患者106例为实验组.同时,收集体检健康者30例为对照组.采用酶联免疫吸附双抗体夹心(ELISA)法定量测定血浆中凝血酶激活的纤溶抑制物抗原(TAFI:Ag)及TAT水平.结果 实验组血浆TAFI:Ag及TAT水平分别为(30.0±2.5)μg/mL及(36.3±3.4)ng/mL,对照组血浆TAFI:Ag及TAT水平分别为(22.5±2.5)μg/mL及24.5±2.5 ng/mL,有显著性差异(P<0.05).胃癌患者TAFI抗原及TAT水平随临床分期的进展而增高,Spearman秩相关分析提示,其与术后病理分期呈正相关,相关系数分别为0.814及0.881.用ROC曲线研究TAFI抗原和TAT两项指标的检验效能显示:TAFI抗原的临界值为26.25μg/mL(AUC=0.915,P<0.05);TAT的临界值为29.15 ng/mL(AUC=0.852,P<0.05).结论 胃癌患者体内TAFI及TAT水平均显著升高,并与胃癌病理分期呈正相关,提示其作为胃癌诊治的辅助实验室指标或有可观的应用价值.

Levels and Clinical Significances of Thrombin Activated Fibrinolysis Inhibitor ( TAFI ) and Thrombin-antithrombin Complex( TAT) in Gastric Cancer

Objective To study the levels of thrombin activated fibrinolysis inhibitor ( TAFI) and thrombin-antithrombin complex(TAT) in gastric cancer and their relationships with gastric cancer .Methods 106 cases of gastric cancer were the ex-perimental group ,and 30 healthy individuals were the control group .ELISA method was used to detect the levels of TAFI:Ag and TAT.Results The level of TAFI:Ag and TAT in the experimental group respectively were 30.0 ±2.5 μg/mL and 36.3 ±3.4 ng/mL;while the level of TAFI:Ag and TAT in the control group were 22.5 ±2.5μg/mL and 24.5 ±2.5 ng/mL,the differences were statistically significant (P<0.05).The levels of TAFI:Ag and TAT in the experimental group increased along with the de-velopment of gastric cancer .Spearman rank correlation test revealed that the levels of TAFI and TAT were positively correlated with pathological stage,correlation coefficients were 0.814 and 0.881.The cutoff of TAFI:Ag was 26.25μg/mL(AUC=0.915, P<0.05),and the cutoff of TAT was 29.15ng/mL(AUC=0.852,P<0.05).Conclusion The levels of TAFI and TAT in pa-tients with gastric cancer are higher and are positively correlated with pathological stage .TAFI and TAT can be useful lab test in-dexes for gastric cancer .